Company's annual revenue growth of 14.34% outperformed its 3 year CAGR of -2.66%. (Source: Consolidated Financials)
Panacea Biotec Share Price
Panacea Biotec Share Pr...
Panacea Biotec share price insights
Stock gave a 3 year return of -62.7% as compared to Nifty Smallcap 100 which gave a return of 80.38%. (as of last trading session)
Company has spent less than 1% of its operating revenues towards interest expenses and 26.75% towards employee cost in the year ending 31 Mar, 2024. (Source: Consolidated Financials)
Stock generated -62.7% return as compared to Nifty Pharma which gave investors 38.67% return over 3 year time period. (as of last trading session)
Panacea Biotec Ltd. share price moved down by -0.73% from its previous close of Rs 137.33. Panacea Biotec Ltd. stock last traded price is 136.33
Share Price Value Today/Current/Last 136.33 Previous Day 137.33
Key Metrics
PE Ratio (x) | -890.03 | ||||||||||
EPS - TTM (₹) | -0.15 | ||||||||||
MCap (₹ Cr.) | 836.62 | ||||||||||
Sectoral MCap Rank | 74 | ||||||||||
PB Ratio (x) | 1.00 | ||||||||||
Div Yield (%) | 0.00 | ||||||||||
Face Value (₹) | 1.00 | ||||||||||
Beta Beta
| 2.85 | ||||||||||
VWAP (₹) | 136.74 | ||||||||||
52W H/L (₹) |
Panacea Biotec Share Price Returns
1 Day | -0.4% |
1 Week | -2.61% |
1 Month | 3.09% |
3 Months | -0.48% |
1 Year | 9.17% |
3 Years | -61.88% |
5 Years | -5.5% |
Panacea Biotec News & Analysis
Ahead of Market: 10 things that will decide D-Street action on Wednesday
NewsSensex falls! But these stocks rallied over 15% on BSE in today's trade
NewsPanacea Biotec zooms 20% on Rs 1,040-crore order win from UNICEF and PAHO
NewsCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Announcements
Panacea Biotec Share Recommendations
No Recommendations details available for this stock.
Check out other stock recos.
Panacea Biotec Financials
Income (P&L)
Balance Sheet
Cash Flow
Ratios
Insights
Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 14.34% outperformed its 3 year CAGR of -2.66%. (Source: Consolidated Financials)Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 26.75% towards employee cost in the year ending 31 Mar, 2024. (Source: Consolidated Financials)
Quarterly | Annual Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Total Income 147.27 156.18 146.25 135.27 143.99 Total Income Growth (%) -5.70 6.79 8.12 -6.06 11.50 Total Expenses 148.57 156.98 153.12 121.24 124.73 Total Expenses Growth (%) -5.36 2.52 26.29 -2.80 56.85 EBIT -1.30 -0.80 -6.87 14.03 19.26 EBIT Growth (%) - - -148.97 -27.15 -61.19 Profit after Tax (PAT) -1.43 -2.20 -8.29 10.98 -12.68 PAT Growth (%) - - -175.50 - -165.46 EBIT Margin (%) -0.88 -0.51 -4.70 10.37 13.38 Net Profit Margin (%) -0.97 -1.41 -5.67 8.12 -8.81 Basic EPS (₹) -0.23 -0.37 -1.35 1.79 -2.07 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Total Assets 1,240.68 1,271.17 1,782.51 1,178.82 1,390.30 Total Assets Growth (%) -2.40 -28.69 51.21 -15.21 1.07 Total Liabilities 402.45 426.07 932.55 1,407.06 1,191.65 Total Liabilities Growth (%) -5.54 -54.31 -33.72 18.08 17.11 Total Equity 838.23 818.46 845.81 -253.35 173.96 Total Equity Growth (%) 2.42 -3.23 - -245.64 -48.50 Current Ratio (x) 1.57 1.71 1.30 1.20 1.50 Total Debt to Equity (x) 0.02 0.02 0.04 -2.92 3.47 Contingent Liabilities 0.00 644.43 373.48 413.45 368.66 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Net Cash flow from Operating Activities -0.10 -422.45 -108.44 106.76 -30.47 Net Cash used in Investing Activities 10.23 430.33 1,282.57 -47.68 -34.76 Net Cash flow from Financing Activities -2.81 -18.37 -1,175.85 -47.11 90.74 Net Cash Flow 7.32 -10.50 -1.73 11.98 25.51 Closing Cash & Cash Equivalent 47.17 39.85 50.35 52.19 40.22 Closing Cash & Cash Equivalent Growth (%) 18.36 -20.85 -3.53 29.78 178.02 Total Debt/ CFO (x) -209.90 -0.04 -0.28 6.85 -20.14 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Return on Equity (%) -0.13 -4.04 126.99 0.00 -109.75 Return on Capital Employed (%) -3.32 -9.09 -4.75 5.44 1.90 Return on Assets (%) -0.09 -2.61 60.47 -12.52 -13.97 Interest Coverage Ratio (x) 1.60 -10.43 -0.02 0.22 0.10 Asset Turnover Ratio (x) 0.45 0.30 0.24 53.00 39.13 Price to Earnings (x) -666.67 -20.00 0.84 -7.36 -3.45 Price to Book (x) 0.88 0.81 1.07 -4.34 3.79 EV/EBITDA (x) 108.23 -9.81 -122.86 19.43 19.57 EBITDA Margin (%) 1.02 -10.06 -0.43 13.86 11.22
Panacea Biotec Peer Comparison
Panacea Biotec Stock Performance
Ratio Performance
Insights
Stock Returns vs Nifty Smallcap 100
Stock gave a 3 year return of -62.7% as compared to Nifty Smallcap 100 which gave a return of 80.38%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated -62.7% return as compared to Nifty Pharma which gave investors 38.67% return over 3 year time period. (as of last trading session)
Choose from Peers
Choose from Stocks
- 1D
- 1W
- 1M
- 3M
- 6M
- 1Y
- 5Y
Loading...Insights
Stock Returns vs Nifty Smallcap 100
Stock gave a 3 year return of -62.7% as compared to Nifty Smallcap 100 which gave a return of 80.38%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated -62.7% return as compared to Nifty Pharma which gave investors 38.67% return over 3 year time period. (as of last trading session)
See All Parameters
MF Ownership
MF Ownership details are not available.
Corporate Actions
Panacea Biotec Board Meeting/AGM
Panacea Biotec Dividends
- Others
Meeting Date Announced on Purpose Details May 30, 2024 May 13, 2024 Board Meeting Audited Results Feb 13, 2024 Jan 30, 2024 Board Meeting Quarterly Results Nov 10, 2023 Oct 23, 2023 Board Meeting Quarterly Results Sep 29, 2023 Aug 14, 2023 AGM A.G.M. Aug 12, 2023 Jul 31, 2023 Board Meeting Quarterly Results Type Dividend Dividend per Share Ex-Dividend Date Announced on Final 75% 0.75 Sep 19, 2011 May 13, 2011 Final 25% 0.25 Sep 16, 2010 May 07, 2010 Final 100% 1.0 Sep 19, 2008 Jun 27, 2008 Final 100% 1.0 Sep 21, 2007 Jun 14, 2007 Final 100% 1.0 Sep 22, 2006 May 23, 2006 All Types Ex-Date Record Date Announced on Details Splits Feb 03, 2003 Feb 11, 2003 Oct 26, 2002 Split: Old FV10.0| New FV:1.0
About Panacea Biotec
Panacea Biotec Ltd., incorporated in the year 1984, is a Small Cap company (having a market cap of Rs 841.16 Crore) operating in Pharmaceuticals sector. Panacea Biotec Ltd. key Products/Revenue Segments include Vaccines, Pharmaceutical Preparations, Scrap and Export Incentives for the year ending 31-Mar-2023. Show More
Executives
Auditors
- RJ
Rajesh Jain
Chairman & Managing DirectorSJSandeep Jain
Joint Managing DirectorAJAnkesh Jain
Whole Time DirectorBSBhupinder Singh
Non Executive DirectorShow More - Walker Chandiok & Co. LLP
Industry
Key Indices Listed on
BSE SmallCap, BSE Healthcare, BSE AllCap, + 1 more
Address
Ambala-Chandigarh Highway,Lalru, Punjab - 140501
More Details
FAQs about Panacea Biotec share
- 1. What's Panacea Biotec share price today and what are Panacea Biotec share returns ?Panacea Biotec share price was Rs 136.33 as on 18 Jul, 2024, 12:16 PM IST. Panacea Biotec share price was down by 0.73% based on previous share price of Rs. 137.47. In last 1 Month, Panacea Biotec share price moved up by 2.74%.
- 2. Who owns Panacea Biotec?Following are the key changes to Panacea Biotec shareholding:
- Promoter holding has not changed in last 9 months and holds 73.59 stake as on 31 Mar 2024
- Domestic Institutional Investors holding has gone up from 0.54 (30 Jun 2023) to 0.84 (31 Mar 2024)
- Foreign Institutional Investors holding has gone up from 0.22 (30 Jun 2023) to 0.27 (31 Mar 2024)
- Other investor holding have gone down from 25.64 (30 Jun 2023) to 25.29 (31 Mar 2024)
- 3. What's the market capitalization of Panacea Biotec?Within the Pharmaceuticals sector, Panacea Biotec stock has a market cap rank of 74. Panacea Biotec has a market cap of Rs 833.62 Cr.
- 4. What is Panacea Biotec's 52 week high / low?52 Week high of Panacea Biotec share is Rs 202.50 while 52 week low is Rs 112.35
- 5. Who's the chairman of Panacea Biotec?Rajesh Jain is the Chairman & Managing Director of Panacea Biotec
- 6. Who are the peers for Panacea Biotec in Pharmaceuticals sector?Top 10 Peers for Panacea Biotec are Ind-Swift Laboratories Ltd., Albert David Ltd., Jagsonpal Pharmaceuticals Ltd., Bajaj Healthcare Ltd., Nectar Lifesciences Ltd., Wanbury Ltd., Medicamen Biotech Ltd., Kilitch Drugs(I) Ltd., Zim Laboratories Ltd. and Venus Remedies Ltd.
- 7. What are the returns for Panacea Biotec share?Return Performance of Panacea Biotec Shares:
- 1 Week: Panacea Biotec share price moved down by 2.93%
- 1 Month: Panacea Biotec share price moved up by 2.74%
- 3 Month: Panacea Biotec share price moved down by 0.81%
- 6 Month: Panacea Biotec share price moved down by 20.16%
- 8. What is the PE & PB ratio of Panacea Biotec?The PE ratio of Panacea Biotec stands at -894.85, while the PB ratio is 1.0.
- 9. How can I quickly analyze Panacea Biotec stock?Panacea Biotec share can be quickly analyzed on following metrics:
- Stock's PE is -889.31
- Price to Book Ratio of 1.00
- 10. What are the Panacea Biotec quarterly results?On Consoldiated basis, Panacea Biotec reported a total income and loss of Rs 147.27 Cr and Rs -1.43 respectively for quarter ending 2024-03-31. Total Income and loss for the year ending 2024-03-31 was Rs 584.97 Cr and Rs -1.17 Cr.
- 11. What dividend is Panacea Biotec giving?Panacea Biotec Ltd. announced an equity dividend of 75% on a face value of 1.0 amounting to Rs 0.75 per share on 13 May 2011. The ex dividend date was 19 Sep 2011.
- 12. What is the CAGR of Panacea Biotec?The CAGR of Panacea Biotec is -2.74.
Trending in Markets
Panacea Biotec Quick Links
Equity Quick Links
More from Markets
IPOStock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.